Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Si-Yang Liu, Hua Bao, Qun Wang, Wei-Min Mao, Yedan Chen, Xiaoling Tong, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Song Dong, Xu-Chao Zhang, Jian Su, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Xue Wu, Yang Shao, Wen-Zhao Zhong () and Yi-Long Wu ()
Additional contact information
Si-Yang Liu: South China University of Technology
Hua Bao: Nanjing Geneseeq Technology Inc.
Qun Wang: Fudan University Affiliated Zhongshan Hospital
Wei-Min Mao: Zhejiang Cancer Hospital
Yedan Chen: Nanjing Geneseeq Technology Inc.
Xiaoling Tong: Nanjing Geneseeq Technology Inc.
Song-Tao Xu: Fudan University Affiliated Zhongshan Hospital
Lin Wu: Hunan Cancer Hospital
Yu-Cheng Wei: The Affiliated Hospital of Medical College Qingdao University
Yong-Yu Liu: Shenyang Chest Hospital
Chun Chen: Fujian Medical University Union Hospital
Ying Cheng: Jilin Provincial Tumor Hospital
Rong Yin: Jiangsu Cancer Hospital
Fan Yang: The People’s Hospital of Peking University
Sheng-Xiang Ren: Shanghai Pulmonary Hospital
Xiao-Fei Li: Tangdu Hospital
Jian Li: Peking University First Hospital
Cheng Huang: Fujian Cancer Hospital
Zhi-Dong Liu: Beijing Chest Hospital
Shun Xu: The First Hospital of China Medical University
Ke-Neng Chen: Beijing Cancer Hospital
Shi-Dong Xu: Harbin Medical University Cancer Hospital
Lun-Xu Liu: West China Hospital of Sichuan University
Ping Yu: Sichuan Cancer Hospital
Bu-Hai Wang: The Northern Jiangsu People’s Hospital
Hai-Tao Ma: The First Affiliated Hospital of Suzhou University
Hong-Hong Yan: South China University of Technology
Song Dong: South China University of Technology
Xu-Chao Zhang: South China University of Technology
Jian Su: South China University of Technology
Jin-Ji Yang: South China University of Technology
Xue-Ning Yang: South China University of Technology
Qing Zhou: South China University of Technology
Xue Wu: Nanjing Geneseeq Technology Inc.
Yang Shao: Nanjing Geneseeq Technology Inc.
Wen-Zhao Zhong: South China University of Technology
Yi-Long Wu: South China University of Technology

Nature Communications, 2021, vol. 12, issue 1, 1-11

Abstract: Abstract The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising the necessity for further biomarker assessment. In this work, by comprehensive genomic profiling of 171 tumor tissues from the ADJUVANT trial, five predictive biomarkers are identified (TP53 exon4/5 mutations, RB1 alterations, and copy number gains of NKX2-1, CDK4, and MYC). Then we integrate them into the Multiple-gene INdex to Evaluate the Relative benefit of Various Adjuvant therapies (MINERVA) score, which categorizes patients into three subgroups with relative disease-free survival and overall survival benefits from either adjuvant gefitinib or chemotherapy (Highly TKI-Preferable, TKI-Preferable, and Chemotherapy-Preferable groups). This study demonstrates that predictive genomic signatures could potentially stratify resected EGFR-mutant NSCLC patients and provide precise guidance towards future personalized adjuvant therapy.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26806-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26806-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26806-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().